转移性透明细胞肾细胞癌一线免疫联合方案治疗后二线治疗的无进展生存期
在纪念斯隆-凯特琳癌症中心回顾性评估173例接受一线免疫/免疫(伊匹木单抗联合纳武利尤单抗)或酪氨酸激酶抑制剂/免疫联合治疗的转移性透明细胞肾细胞癌患者的二线治疗无进展生存期(PFS-2)、总生存期及二线客观缓解率。二线客观缓解率免疫/免疫组显著高于酪氨酸激酶抑制剂/免疫组(47% vs 13%,p<0.001),但倾向性评分校正后PFS-2的受限平均生存时间及总生存期的受限平均生存时间均无显著差异。
要点
- 二线客观缓解率免疫/免疫组47% vs 酪氨酸激酶抑制剂/免疫组13%(p<0.001)。
- 倾向性评分校正后PFS-2受限平均生存时间33 vs 30个月,差值2.6个月(95%CI:-2.6,7.9),p=0.3。
- 倾向性评分校正后总生存期受限平均生存时间38 vs 37个月,差值1.0个月(95%CI:-3.4,5.5),p=0.7。
核心结论
- 这些发现不支持改变当前免疫/免疫与酪氨酸激酶抑制剂/免疫治疗策略的临床使用方式。
研究设计与样本
- 在纪念斯隆-凯特琳癌症中心回顾性评估173例接受一线免疫/免疫或酪氨酸激酶抑制剂/免疫治疗的转移性透明细胞肾细胞癌患者,按一线治疗类别分组报告PFS-2、总生存期及二线客观缓解率。
主要发现
- 二线客观缓解率免疫/免疫组显著高于酪氨酸激酶抑制剂/免疫组(47% vs 13%,p<0.001)。
- 酪氨酸激酶抑制剂/免疫组与免疫/免疫组中位PFS-2无显著差异(44 vs 23个月,log-rank p=0.1)。
- 倾向性评分校正后PFS-2受限平均生存时间酪氨酸激酶抑制剂/免疫组33个月 vs 免疫/免疫组30个月,差值2.6个月(95%CI:-2.6,7.9),p=0.3。
- 倾向性评分校正后总生存期受限平均生存时间酪氨酸激酶抑制剂/免疫组38个月 vs 免疫/免疫组37个月,组间差值1.0个月(95%CI:-3.4,5.5),p=0.7。
关键数值与推荐
- 免疫/免疫为伊匹木单抗联合纳武利尤单抗,酪氨酸激酶抑制剂/免疫为血管内皮生长因子受体靶向酪氨酸激酶抑制剂联合免疫检查点抑制剂。
- PFS-2用于评估二线治疗挽救长期生存的能力。
临床怎么用
- 作者认为这些发现不支持改变当前免疫/免疫与酪氨酸激酶抑制剂/免疫治疗策略的临床使用方式。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunotherapy (IO)-based combinations used to treat metastatic clear cell renal cell carcinoma (ccRCC) include dual immune checkpoint inhibition with ipilimumab and nivolumab (IO/IO) and several combinations of vascular endothelial growth factor receptor-targeting tyrosine kinase inhibitors (TKIs) with an immune checkpoint inhibitor (TKI/IO). IO/IO and TKI/IO approaches have not been compared directly, and it is unknown whether patients who do not respond to first-line IO/IO can salvage long-term survival by receiving a second-line TKI. Progression-free survival after second-line therapy (PFS-2) evaluates the ability to be salvaged by second-line therapy. We retrospectively evaluated 173 patients treated with first-line IO/IO or TKI/IO for metastatic ccRCC at Memorial Sloan Kettering Cancer Center and report PFS-2, overall survival, and response to second line of therapy (ORR2nd) for groups defined by first-line category. Although ORR2nd was significantly higher with IO/IO than with TKI/IO (47% vs 13%, p < 0.001), there was no significant difference in median PFS-2 for TKI/IO versus IO/IO (44 vs 23 mo, log-rank p = 0.1) or restricted mean survival time (RMST) for PFS-2 when adjusted for propensity score (33 vs 30 mo; difference 2.6 mo [95% confidence interval {CI}: -2.6, 7.9]; p = 0.3). There was also no significant difference in RMST for overall survival when adjusted for propensity score (38 vs 37 mo; group difference 1.0 mo [95% CI: -3.4, 5.5]; p = 0.7). These findings do not support a change in current utilization practices for IO/IO and TKI/IO treatment strategies for ccRCC. PATIENT SUMMARY: In cases of metastatic clear cell renal cell carcinoma, no significant difference was observed in progression-free survival after second line of therapy between patients receiving ipilimumab plus nivolumab and those receiving a combination of a tyrosine kinase inhibitor and an immune checkpoint inhibitor.
引用
- Fitzgerald KN, Duzgol C, Knezevic A, et al. Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations. Eur Urol. 2022. PMID: 36344318. doi:10.1016/j.eururo.2022.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。